Two Supreme Court decisions, thirteen and fifteen years old, do more to shape a Stevens-Johnson syndrome claim than almost anything in the medical record. Neither is about SJS as such. Both are about generic drugs, and together they hold that federal law preempts state-law failure-to-warn claims and state-law design-defect claims against a generic manufacturer. One of the two arose from a woman who developed toxic epidermal necrolysis after taking a generic anti-inflammatory. Which means that in a case where the reaction is identical, the outcome can turn on a single line in a pharmacy record: whether the pill dispensed was the brand or the copy.
The duty of sameness
Federal law requires a generic drug’s labeling to match the labeling of the brand-name drug it copies. In PLIVA, Inc. v. Mensing, decided in 2011, the Supreme Court held that this requirement makes it impossible for a generic manufacturer to do what state failure-to-warn law would demand of it — strengthen its own warning — and that the state-law claims are therefore preempted.
Two years later, in Mutual Pharmaceutical Co. v. Bartlett, the Court extended the reasoning to design-defect claims. The plaintiff there had been prescribed sulindac, a non-steroidal anti-inflammatory, and received the generic version. She developed toxic epidermal necrolysis. A jury found for her and the First Circuit affirmed; the Supreme Court reversed, holding that a generic manufacturer could neither redesign the drug nor change the label, so the state-law claim asked it to do something federal law forbade.
Read together, the two decisions do not say that a generic drug is safe, or that the warning was adequate. They say something narrower and, for a claimant, harder: that a court cannot impose liability on the company that made the pill for failing to warn about or redesign it.
Why this lands so heavily on SJS/TEN
The medications most often associated with SJS/TEN are, by and large, old and widely genericized — lamotrigine, carbamazepine, phenytoin, allopurinol, sulfonamide antibiotics. These are not new brand-name products under patent. They are inexpensive drugs dispensed as generics most of the time, which is exactly the population the two decisions reach.
So the first substantive question in one of these cases is not a medical one. It is documentary: what did the pharmacy actually hand over? The prescription may name the brand. The label on the bottle, the pharmacy’s dispensing record and the manufacturer’s national drug code identify what was dispensed. In a hospital, the medication administration record does the same job.
What is left when the answer is “generic”
Less, and not nothing. The two holdings are about the manufacturer of the generic product and about two particular theories. They do not address every claim a person injured by a medication might bring, and they do not touch claims against a brand-name manufacturer at all. Where the drug dispensed was the brand, Mensing and Bartlett are simply not the obstacle.
That is why we ask for pharmacy records early, and why we do not tell anyone over the phone that they have a case or that they do not. The answer to a legal question this specific is in a record neither of us has read yet.
The part nobody should have to know
It is worth saying plainly that none of this has anything to do with the patient. A person who took a tablet a doctor prescribed, and lost their skin and possibly their sight to it, did not choose the version. Under federal generic-substitution rules they frequently had no say in it at all. Whether a legal remedy exists can nonetheless depend on that substitution — which is a fair criticism of the state of the law, and also the state of the law. Our page on Stevens-Johnson syndrome explains what we look for and what we can and cannot promise about it.
This article is general information about how these cases work. It is not legal advice, it does not create an attorney-client relationship, and no two claims are alike. If something here sounds like your situation, the useful next step is a conversation about the facts.
